122 related articles for article (PubMed ID: 38647197)
21. Correlations between APOE4 allele and regional amyloid and tau burdens in cognitively normal older individuals.
Hong YJ; Kim CM; Lee JH; Sepulcre J
Sci Rep; 2022 Aug; 12(1):14307. PubMed ID: 35995824
[TBL] [Abstract][Full Text] [Related]
22. Role of family history for Alzheimer biomarker abnormalities in the adult children study.
Xiong C; Roe CM; Buckles V; Fagan A; Holtzman D; Balota D; Duchek J; Storandt M; Mintun M; Grant E; Snyder AZ; Head D; Benzinger TL; Mettenburg J; Csernansky J; Morris JC
Arch Neurol; 2011 Oct; 68(10):1313-9. PubMed ID: 21987546
[TBL] [Abstract][Full Text] [Related]
23. Alzheimer's disease prevention: Apolipoprotein e4 moderates the effect of physical activity on brain beta-amyloid deposition in healthy older adults.
Pedrero-Chamizo R; Zhuang K; Juarez A; Janabi M; Jagust WJ; Landau SM
J Sci Med Sport; 2024 Jun; 27(6):402-407. PubMed ID: 38664148
[TBL] [Abstract][Full Text] [Related]
24. Cognitively healthy APOE4/4 carriers show white matter impairment associated with serum NfL and amyloid-PET.
Tato-Fernández C; Ekblad LL; Pietilä E; Saunavaara V; Helin S; Parkkola R; Zetterberg H; Blennow K; Rinne JO; Snellman A
Neurobiol Dis; 2024 Mar; 192():106439. PubMed ID: 38365046
[TBL] [Abstract][Full Text] [Related]
25. Associations between white matter microstructure and amyloid burden in preclinical Alzheimer's disease: A multimodal imaging investigation.
Racine AM; Adluru N; Alexander AL; Christian BT; Okonkwo OC; Oh J; Cleary CA; Birdsill A; Hillmer AT; Murali D; Barnhart TE; Gallagher CL; Carlsson CM; Rowley HA; Dowling NM; Asthana S; Sager MA; Bendlin BB; Johnson SC
Neuroimage Clin; 2014; 4():604-14. PubMed ID: 24936411
[TBL] [Abstract][Full Text] [Related]
26.
Erickson CM; Schultz SA; Oh JM; Darst BF; Ma Y; Norton D; Betthauser T; Gallagher CL; Carlsson CM; Bendlin BB; Asthana S; Hermann BP; Sager MA; Blennow K; Zetterberg H; Engelman CD; Christian BT; Johnson SC; Dubal DB; Okonkwo OC
Neurology; 2019 Apr; 92(16):e1878-e1889. PubMed ID: 30867273
[TBL] [Abstract][Full Text] [Related]
27. Association of sex and APOE ε4 with brain tau deposition and atrophy in older adults with Alzheimer's disease.
Yan S; Zheng C; Paranjpe MD; Li J; Benzinger TLS; Lu J; Zhou Y
Theranostics; 2020; 10(23):10563-10572. PubMed ID: 32929366
[TBL] [Abstract][Full Text] [Related]
28. Genome-wide association study of brain amyloid deposition as measured by Pittsburgh Compound-B (PiB)-PET imaging.
Yan Q; Nho K; Del-Aguila JL; Wang X; Risacher SL; Fan KH; Snitz BE; Aizenstein HJ; Mathis CA; Lopez OL; Demirci FY; Feingold E; Klunk WE; Saykin AJ; ; Cruchaga C; Kamboh MI
Mol Psychiatry; 2021 Jan; 26(1):309-321. PubMed ID: 30361487
[TBL] [Abstract][Full Text] [Related]
29. Diabetes and hypertension are related to amyloid-beta burden in the population-based Rotterdam Study.
van Arendonk J; Neitzel J; Steketee RME; van Assema DME; Vrooman HA; Segbers M; Ikram MA; Vernooij MW
Brain; 2023 Jan; 146(1):337-348. PubMed ID: 36374264
[TBL] [Abstract][Full Text] [Related]
30. Relationship Between Body Mass Index, ApoE4 Status, and PET-Based Amyloid and Neurodegeneration Markers in Amyloid-Positive Subjects with Normal Cognition or Mild Cognitive Impairment.
Blautzik J; Kotz S; Brendel M; Sauerbeck J; Vettermann F; Winter Y; Bartenstein P; Ishii K; Rominger A;
J Alzheimers Dis; 2018; 65(3):781-791. PubMed ID: 28697560
[TBL] [Abstract][Full Text] [Related]
31. Quantitative longitudinal interrelationships between brain metabolism and amyloid deposition during a 2-year follow-up in patients with early Alzheimer's disease.
Förster S; Yousefi BH; Wester HJ; Klupp E; Rominger A; Förstl H; Kurz A; Grimmer T; Drzezga A
Eur J Nucl Med Mol Imaging; 2012 Dec; 39(12):1927-36. PubMed ID: 22926714
[TBL] [Abstract][Full Text] [Related]
32. Multiple Effect of APOE Genotype on Clinical and Neuroimaging Biomarkers Across Alzheimer's Disease Spectrum.
Liu Y; Tan L; Wang HF; Liu Y; Hao XK; Tan CC; Jiang T; Liu B; Zhang DQ; Yu JT;
Mol Neurobiol; 2016 Sep; 53(7):4539-47. PubMed ID: 26298664
[TBL] [Abstract][Full Text] [Related]
33. Serum zinc levels and in vivo beta-amyloid deposition in the human brain.
Kim JW; Byun MS; Yi D; Lee JH; Kim MJ; Jung G; Lee JY; Kang KM; Sohn CH; Lee YS; Kim YK; Lee DY;
Alzheimers Res Ther; 2021 Nov; 13(1):190. PubMed ID: 34798903
[TBL] [Abstract][Full Text] [Related]
34. Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease.
Drzezga A; Grimmer T; Henriksen G; Mühlau M; Perneczky R; Miederer I; Praus C; Sorg C; Wohlschläger A; Riemenschneider M; Wester HJ; Foerstl H; Schwaiger M; Kurz A
Neurology; 2009 Apr; 72(17):1487-94. PubMed ID: 19339712
[TBL] [Abstract][Full Text] [Related]
35. 18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons.
Knopman DS; Jack CR; Wiste HJ; Lundt ES; Weigand SD; Vemuri P; Lowe VJ; Kantarci K; Gunter JL; Senjem ML; Mielke MM; Roberts RO; Boeve BF; Petersen RC
Neurobiol Aging; 2014 Sep; 35(9):2096-106. PubMed ID: 24702820
[TBL] [Abstract][Full Text] [Related]
36. White matter hyperintensities and cerebral amyloidosis: necessary and sufficient for clinical expression of Alzheimer disease?
Provenzano FA; Muraskin J; Tosto G; Narkhede A; Wasserman BT; Griffith EY; Guzman VA; Meier IB; Zimmerman ME; Brickman AM;
JAMA Neurol; 2013 Apr; 70(4):455-61. PubMed ID: 23420027
[TBL] [Abstract][Full Text] [Related]
37. Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging.
Ossenkoppele R; Smith R; Mattsson-Carlgren N; Groot C; Leuzy A; Strandberg O; Palmqvist S; Olsson T; Jögi J; Stormrud E; Cho H; Ryu YH; Choi JY; Boxer AL; Gorno-Tempini ML; Miller BL; Soleimani-Meigooni D; Iaccarino L; La Joie R; Baker S; Borroni E; Klein G; Pontecorvo MJ; Devous MD; Jagust WJ; Lyoo CH; Rabinovici GD; Hansson O
JAMA Neurol; 2021 Aug; 78(8):961-971. PubMed ID: 34180956
[TBL] [Abstract][Full Text] [Related]
38. Brain imaging measurements of fibrillar amyloid-β burden, paired helical filament tau burden, and atrophy in cognitively unimpaired persons with two, one, and no copies of the APOE ε4 allele.
Ghisays V; Goradia DD; Protas H; Bauer RJ; Devadas V; Tariot PN; Lowe VJ; Knopman DS; Petersen RC; Jack CR; Caselli RJ; Su Y; Chen K; Reiman EM
Alzheimers Dement; 2020 Apr; 16(4):598-609. PubMed ID: 31831374
[TBL] [Abstract][Full Text] [Related]
39. A Network of Genetic Effects on Non-Demented Cognitive Aging: Alzheimer's Genetic Risk (CLU + CR1 + PICALM) Intensifies Cognitive Aging Genetic Risk (COMT + BDNF) Selectively for APOEɛ4 Carriers.
Sapkota S; Dixon RA
J Alzheimers Dis; 2018; 62(2):887-900. PubMed ID: 29480189
[TBL] [Abstract][Full Text] [Related]
40. Effect of APOE ε4 genotype on amyloid-β, glucose metabolism, and gray matter volume in cognitively normal individuals and amnestic mild cognitive impairment.
Li W; Li R; Yan S; Zhao Z; Shan Y; Qi Z; Lu J;
Eur J Neurol; 2023 Mar; 30(3):587-596. PubMed ID: 36448771
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
